Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

One down, two to go
November 2019
SHARING OPTIONS:

GLASGOW, Scotland—The first cohort of patients for a Phase 2a clinical study of MGB Biopharma’s MGB-BP-3 antibiotic has completed treatment, the company reported last month. The open-label trial is evaluating the safety, tolerability and efficacy of incremental doses of MGB-BP-3 in patients with Clostridium difficile-associated disease (CDAD), and thus far the data point to high efficacy and good tolerability in the first cohort. Recruitment for the second of three cohorts is underway in the United States and Canada. MGB-BP-3 has a novel mode of action and has demonstrated strong bactericidal activity against BI/NAP1/027, the most virulent strain of C. difficile and one that is largely antibiotic-resistant.
 
Dr. Miroslav Ravic, CEO of MGB Biopharma, said in part that, “Given its unique properties, we remain confident that MGB-BP-3 could represent a new paradigm for the treatment of CDAD, a potentially life-threatening infection.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.